Results 241 to 250 of about 41,710 (302)

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, Volume 43, Issue 5, May 2026.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway. [PDF]

Biochem Biophys Rep
Lee M, Tariq AR, Kim M.
europepmc   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3692-3702, May 2026.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes. [PDF]

J Clin Med
Nagayama D, Kawana H, Watanabe Y, Horikawa O, Ohira M, Saiki A.   +5 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3703-3715, May 2026.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3807-3818, May 2026.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3974-3984, May 2026.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Cognitive Functions, Brain-Derived Neurotrophic Factor, and Pentraxin-3 Levels in Patients With Type 2 Diabetes. [PDF]

Cureus
Demirkılıç O, Eski İ, Çiftçi Öztürk E, Yasun Ö, Aydın B, Birkan C, Özsoy A, Şen S.   +7 more
europepmc   +1 more source